WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights.
which were partially offset by a $15.0 million one-time expense in the first quarter related to the discontinuation of systemic pegcetacoplan for cold agglutinin disease (CAD). Selling, General and ...
Cold agglutinin disease is under clinical development by NovelMed Therapeutics and currently in Phase I for Acquired (Autoimmune) Hemolytic Anemia. According to GlobalData, Phase I drugs for Acquired ...
Medpage Today on MSN1d
Investigational Drugs for Chronic Inflammatory Demyelinating PolyneuropathyInvestigational therapies may soon change the treatment landscape for chronic inflammatory demyelinating polyneuropathy (CIDP ...
Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure
Department of Pediatrics (I.V.-A., A.E.S., T.S., A.M.G., C.P., M.A.S., J.H., J.D.M., B.C.B.), University of Cincinnati College of Medicine, OH. Ohio Heart Institute ...
There is high variability in published utility estimates in Huntington disease (HD), according to a new study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback